NCT05394974

Brief Summary

Joint consultations appeared a few years ago in routine medical practice, but they are still not widely used and rarely evaluated. The primary purpose of the study is to evaluate the impact for the patient of the presence of a clinical psychologist during the joint consultation. The secondary purpose is to evaluate the impact for the patient and for the neurologist of the presence of a clinical psychologist during the joint consultation

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2021

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

May 23, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 27, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2023

Completed
Last Updated

June 13, 2022

Status Verified

May 1, 2022

Enrollment Period

2 years

First QC Date

May 23, 2022

Last Update Submit

June 10, 2022

Conditions

Keywords

Joint neurologistpsychologist consultationneurodegenerative and/or neurogenetic disease

Outcome Measures

Primary Outcomes (1)

  • Patient satisfaction after the consultation assessed by 3 questions on a Likert scale

    5-point Likert scale from which to select a response : 1. Very satisfied. 2. Moderately satisfied. 3. Neither satisfied nor dissatisfied. 4. Moderately dissatisfied. 5. Very dissatisfied.

    After consultation et 1 to 3 months later

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patient with a neurodegenerative and/or neurogenetic disease

You may qualify if:

  • patient with a neurodegenerative and/or neurogenetic disease
  • adult patient

You may not qualify if:

  • dementia
  • age \<18 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service de Neurologie - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Neurodegenerative Diseases

Condition Hierarchy (Ancestors)

Nervous System Diseases

Study Officials

  • Mathieu ANHEIM, MD, PhD

    Service de Neurologie - CHU de Strasbourg - France

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 23, 2022

First Posted

May 27, 2022

Study Start

June 1, 2021

Primary Completion

June 1, 2023

Study Completion

June 1, 2023

Last Updated

June 13, 2022

Record last verified: 2022-05

Locations